

15^{es}

JOURNÉES
FRANCOPHONES
Alvéole

Le réentraînement à l'effort avec ventilation à haut débit nasal est_(-il) plus efficace_(?)

f.herengt@dieulefit-sante.org

alvéole
OBEZ UN SOUFFLE NOUVEAU

Groupes de travail de la SPLF
pour l'Exercice et Réhabilitation
Respiratoire

SPLF
Société de Pneumologie
de Langue Française

- Lien d'intérêt: Fisher Paykel Healthcare, New Zealand

17 décembre 1903, 1^{er} vol aérien de 12''



Les types: mixeurs, turbines, Venturi

Générateur de flux (B)



Mixeurs avec débitmètre mécanique (A,D)



Mélangeur avec réglage de la FiO2 (E)





Mélangeur à effet Venturi (C,F)

OHD permet la maîtrise de l'oxygénation (FiO_2 , SpO_2) ↗

Oxygénothérapie standard

Oxygénothérapie à haut débit (OHD)

Détresse respiratoire aiguë :
débit inspiratoire de pointe (35L/mn)





OHD :

- Couverture de la demande ventilatoire (35L/mn)
- FiO₂ inspirée = FiO₂ réglée

OHD augmente le rinçage de l'espace mort anatomique

- Apnée après inhalation de Krypton marqué sans et avec NHF



OHD produit une pression positive (effet PEP)




Fig. 4. Example airway pressure profiles from one patient, with mouth open or mouth closed, at flows of 30, 40, and 50 L/min.

- le volume pulmonaire de fin d'expiration (CRF).
- le volume courant (VT)
- le recrutement alvéolaire.
- Limite le risque d'atélectasie.

Les effets physiologiques de l'OHD

Haut débit

Oxygénation

Rinçage espace mort anatomique

Effet PEP

↘ Raw

↘ W ventilatoire

↗ Recrutement alvéolaire

Humidification

↗ escalator mucociliaire

↗ température & humidité

↗ confort

↗ défenses tissulaires locales

↘ sécrétions

↘ W conditionnement des gaz

OHD et exercice chez les patients BPCO

Cirio 2016: OHD vs O2

- N=12 BPCO, VEMS#40 %; Randomisé crossover 2 tests d'endurance P_{cst} à 75 % de P_{max} cycloergometref







Fig. 1. Effect of the HFNC on exercise capacity during a constant-load test compared to a control condition in which the test was performed at the same FiO₂. In all patient HFNC significantly increased the exercise performance. T_{lim} = exercise duration. Solid line = mean value.



- N=12 BPCO, VEMS#40 %; Randomisé crossover 2 tests d'endurance P_{cst} à 75 % de P_{max} cycloergometre
- OHD vs O₂ (FiO₂<>, optiflow vs venturi)
 - Temps endurance ↗
 - Dyspnée et fatigue isotime ↘

Cirio S, Piran M, Vitacca M, Piaggi G, Ceriana P, Prazzoli M, Paneroni M, Carlucci A. Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation. *Respir Med.* 2016 Sep;118:128-132. doi: 10.1016/j.rmed.2016.08.004. Epub 2016 Aug 8. PMID: 27578482.

DellEra 2019: OHD vs O2






- N=28 BPCO, VEMS# 44%
- Randomisé crossover, tapis/90% de Vitesse max
- OHD vs O2 (VM)
- OHD vs O2(VM)
 - Tolérance exercice ↗ vitesse.max. ↗ (5.9 vs. 5.7 km/h; p = 0.0002)
 - Oxygénation
 - Dyspnée isotime ↘

Silvina, Dell’Era, Roux Nicolás, Gimeno Elena, Terrasa Sergio, Castellano Barneche María Florencia, Balestrieri María Carolina, Gracia Guadalupe, Bykhovsky Ilona and Midley Alejandro. “The High Flow Nasal Cannula Improves the Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease: Randomized, Crossover Clinical Trial.” (2019).

Bitos 2021: 79 BPCO modérés OHD vs O2

FIGURE 3 | Changes in physiologic variables over the course of exercise in per-protocol analyses. Means and SD bars are shown for values at rest, at isotime (i.e., end-exercise time in tests with shorter endurance and corresponding time in tests with longer endurance), and at end-exercise. Open circles represent tests with high-flow, closed circles with low-flow oxygen therapy. **(A-C)** Depict pulse oximetry (SpO₂), breath rate and heart rate. **P* < 0.05 vs. rest within same treatment, †*P* < 0.05 high-flow vs. low-flow oxygen therapy at corresponding stage of exercise.



Randomisé cross over
BPCO stable, test endurance à 75% Pmax
O2 3l/min vs OHD (60 L/min, FiO2 0.45)

n=79 , âge 58, VEMS#63%
Tlim O2= 688 ± 463''; Tlim OHD=773 ± 471''; Diff.= 13%
Isotime, FR & SpO2 meilleurs dans groupe OHD

Vitaca 2020: High-Flow Oxygen Therapy During Exercise Training in Patients With COPD: A Multicenter Randomized Controlled Trial

• Méthode:

- 137 BPCO, 8 centres, essai randomisé contrôlé
- Entraînement supervisé sur cycloergomètre, 20 séances, **FiO2 <>**

• Mesures pré & post:


- Temps d'endurance (Tlim), TM6,

• Résultats:

- Tlim: NS
- TM6: 17 m

• Conclusion:

- Bénéfice clinique évident avec OHD
- Étude considérée non négative selon p



L
V
C

Temps d'endurance, oxygénation ↗
Dyspnée, Fatigue M inf. ↘

OHD et exercice chez les patients atteints de fibrose

La contrainte ventilatoire dans la fibrose pulmonaire



- **Fréquence ↗↗**
- **travail ventilatoire ↗↗**
- **SpO2 ↘↘**

- **Fréquence ↘↘**
- **travail ventilatoire ↘↘**
- **SpO2 ↗↗**

Badenes 2021: OHD & exercice dans la fibrose




Fig. 2 Endurance time (seconds) with standard oxygen therapy and HFNC during CPET. HFNC high-flow nasal cannula, CPET cardiopulmonary exercise test. Data are presented as mean and standard deviation







Fig. 3 Peripheral muscle oxygen saturation (StO₂) measured by NIRS during CPET performance with both oxygen devices (n = 7). StO₂ muscle oxygen saturation, NIRS near-infrared spectroscopy device, CPET cardiopulmonary exercise test, HFNC high-flow nasal cannula. *p < 0.05. Data are presented as mean and standard deviation

- ✓ Endurance time significantly greater (30%) with NHFO₂ vs standard O₂ therapy
- ✓ Higher peripheral muscle O₂ saturation with NHFO₂ vs standard O₂ therapy

Al chikhanie 2021: OHD & exercice dans la fibrose





Characteristics of the ILD patients.

| | n or mean ± SD |
|---------------------------|----------------|
| Disease category | 18 IPF/7 other |
| LTOT | 18 yes/7 no |
| Sex | 15 ♂/10 ♀ |
| Age (years) | 72.8 ± 6.7 |
| BMI (kg·m ⁻²) | 25.2 ± 5.7 |
| K-BILD | 55.9 ± 22.0 |
| FVC (% predicted) | 62.2 ± 19.6 |
| FEV1 (% predicted) | 67.5 ± 22.0 |
| DLCO (% predicted) | 55.6 ± 24.5 |
| PaO ₂ (kPa) | 8.3 ± 1.4 |



Harada 2022: OHD & exercice dans la fibrose



- N=24, (75% men; age: 77.5 [68.8–83.0])
- OHD (60 l/min, 60%) vs Venturi mask (12 l/min, 50%)
- Charge constante 80% Pmax
- Tlim, FC, Fatigue Minf,
- OHD améliore:
 - Tlim 647'' vs. 577''
 - SpO₂ 96% vs. 94%
 - Fatigue Minf
- **HFNC increased exercise tolerance** in patients with stable IPF experiencing exercise-induced hypoxaemia.



Jumpei Harada, et al. Effect of high-flow nasal cannula oxygen therapy on exercise tolerance in patients with idiopathic pulmonary fibrosis: A randomized crossover trial First published: 02 November 2021 <https://doi.org/10.1111/resp.14176>

NHF02 and exercise capacity in ILD: Yanagita 2024

FIGURE 3 Comparison of exercise duration across three different HFNC conditions: ROOM AIR, FLOW and FLOW + OXYGEN. ROOM AIR is at HFNC setting Flow 0 L/min, FiO₂ 0.21. FLOW is at HFNC setting Flow 40 L/min, FiO₂ 0.21. And FLOW + OXYGEN is the HFNC setting of Flow 40 L/min, FiO₂ 0.6.



L
V
p

Temps d'endurance, oxygénation ↗
Dyspnée, Fatigue M inf. ↘

MERCI !

ESSAI CLINIQUE PIDOX RAPPORT TRIMESTRIEL MARS. 2024

N°IDRCB:
2022-A00774-39


N°SI RIPH 2G:
22.01385.000088

L'étude visant à évaluer l'effet de la **réhabilitation respiratoire** sous **oxygénothérapie à haut débit** sur la **capacité d'exercice** des patients atteints de **fibrose pulmonaire** se poursuit dans notre centre.

A ce jour,

43 inclusions ont été réalisées, dont **35 inclusions complètes**.

COURBE D'INCLUSION



Sur la base d'une inclusion idéale de 3 patients/mois



Recommandation SPLF 2022 - 31


"Il est proposé de prescrire un programme de réhabilitation respiratoire chez un patient ayant un diagnostic confirmé de FPI et présentant une limitation de la capacité à l'exercice et/ou une dyspnée invalidante."

Cottin et al., 2022

Nous avons besoin de **70 patients**
Ayant une **PID bien établie**
Et admis au Centre Dieulefit Santé pour **5 semaines**
de réhabilitation respiratoire

Il nous manque : **27 patients**


INCLUSIONS PAR PROVENANCE



Contact: f.herengt@dieulefit-sante.org

Conclusion:
le réentrainement à l'effort avec ventilation à haut
débit nasal **est plus efficace pour le**
patient

OHD pour le soignant, pour le patient





SOLAR IMPULSE

Un tour du monde en avion grâce
à la seule énergie du Soleil



Bpco: 4 essais

| Ref. | Study design | Type of exercise | NHFT settings | Population | Patients, n | Main results |
|------|--|--|--|---|-------------|---|
| [54] | Prospective nonrandomized trial: HFT vs. low-flow oxygen | CWRT unloaded | Flow 20 L/min, temp 36°C, FiO ₂ 39±11% | Stable severe COPD (FEV ₁ 23% of pred.) | 10 | Increase in exercise endurance with less dyspnea and better oxygenation during HFT |
| [55] | Cross-over RCT: NHFT vs. standard care (ambient air or oxygen therapy) | CWRT at 80% of estimated peak work rate | Flow 60 L/min, temp 31°C, FiO ₂ 0.23±0.03 (n = 9) | Recently discharged with AECOPD (FEV ₁ 29% of pred.) | 19 | No difference in endurance time. Reduced heart rate and nocturnal PtCO ₂ during NHFT |
| [56] | Cross-over RCT: NHFT vs. VM | CWRT at 75% of peak work rate | Flow 58.7 L/min, FiO ₂ 44±11% (n = 8) | Stable severe COPD (FEV ₁ 35% of pred.) with exercise limitation | 12 | Increased endurance time, less dyspnea and leg fatigue, and better oxygenation during NHFT |
| [51] | Cross-over RCT: NHFT vs. VM | IET and CWRT at 90% of maximal speed achieved during the IET | Flow 50 L/min, FiO ₂ 40% | Stable COPD (FEV ₁ 44% of pred.) | 28 | Increased exercise tolerance during both IET and CWRT with less dyspnea, and better oxygenation during NHFT |

NHFT, nasal high-flow therapy; CWRT, constant work rate test, FiO₂, fraction of inspired oxygen; FEV₁, forced expiratory volume in 1 s; RCT, randomized controlled trial; AECOPD, acute exacerbation of COPD; PtCO₂, transcutaneous carbon dioxide pressure; VM, Venturi mask; IET, incremental exercise test.



Chatila W, Chest. 2004

Prieur G, Respirology. 2019

Cirio S, Respir Med. 2016


Dell'Era S, et al Rev Am Med Respir. 2019

Chatila et al. 2004: Test endurance OHD vs O2




- N=10
- O2 puis OHD
- Temps endurance
 - OHD: 10.0 ± 2.4
 - O2: 8.2 ± 4.3 min, $p < 0.05$,
- dyspneic \searrow ($p = 0.03$)
- oxygenation \nearrow

Prieur et al. 2009: Test endurance OHD vs O2



- N=19
- Randomisé crossover
- OHD vs AA (ou O2)
- Temps endurance: NS
- MAIS OHD:
 - FC, PtcCO2, SmO2 ↓
 - Titration O2
- Inconfort explicable
 - Flow
 - température

NHF02 and exercise capacity in ILD



- N=20
- HFNC 50l, FiO₂=0,5 vs venturi 15l, FiO₂=0,5
- Réponse <>
 - Tps_{endurance}
 - SpO₂
 - Dyspnée isotime